Skip to main content

Table 2 Overall Survival and Value of Docetaxel and Ramucirumab in 2nd-line

From: The impact of PD-L1 on survival and value of the immune check point inhibitors in non-small-cell lung cancer; proposal, policies and perspective

Nivo in 2nd-line

OS gains in days/Grade (OS/g) & HR

$4-week Costs

year-Costs

$C/LYG

Generic docetaxel (Doc) 75 mg/m2 vs. supportive care [1]

87/C HR not reported

P = 0.01

$306

6 cycles: $23,868

$98,764

$197,528

12 cycles: $47,736

Ramucirumab (Ramu) + Doc vs. Doc, squamous and non-squamous, (REVEL) [16]

42/D HR 0.86

P = 0.0235

$9333

$121,329

$1,039,963

  1. year-Costs = 4-week Costs of $306 × 13 weeks = $3978
  2. year-Costs of 6 cycles = $3978 × 6 = $23,868
  3. C/LYG yearly-cost/OS gain in days × 360 days
  4. The costs of AEs treatment (AEsTC) were not included
Back to article page